Marion Ferreira

Tours, 37032, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Importance of the delivery route for the tolerability and efficacy of immunomodulatory agents for lung cancer.

Importance of the delivery route for the tolerability and efficacy of immunomodulatory agents for lung cancer.

Journal: Scientific reports

Published: January 22, 2026

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti-TIGIT Antibodies.

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti-TIGIT Antibodies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 21, 2026

A comprehensive evaluation of murine and human ex vivo cultured alveolar macrophages.

A comprehensive evaluation of murine and human ex vivo cultured alveolar macrophages.

Journal: ERJ open research

Published: August 26, 2024

Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.

Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.

Journal: Respiratory medicine and research

Published: August 13, 2024

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 30, 2024

Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer.

Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer.

Journal: Anti-cancer drugs

Published: March 25, 2024

The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.

The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.

Journal: Breathe (Sheffield, England)

Published: March 02, 2024

Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.

Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 13, 2023

Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).

Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 16, 2023

Mucosal administration of anti-bacterial antibodies provide long-term cross-protection against Pseudomonas aeruginosa respiratory infection.

Mucosal administration of anti-bacterial antibodies provide long-term cross-protection against Pseudomonas aeruginosa respiratory infection.

Journal: Mucosal immunology

Published: December 30, 2022

Editorial: Impact of immunotherapy in lung cancer.

Editorial: Impact of immunotherapy in lung cancer.

Journal: Frontiers in oncology

Published: October 29, 2022

Tracheobronchopathia osteochondroplastica: clinical, bronchoscopic, and comorbid features in a case series.

Tracheobronchopathia osteochondroplastica: clinical, bronchoscopic, and comorbid features in a case series.

Journal: BMC pulmonary medicine

Published: July 06, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026